Special Issue "15 Years of Tissue Microarray Technology: The Changing Scenario of Tissue-Based Translational Research"
A special issue of Microarrays (ISSN 2076-3905).
Deadline for manuscript submissions: 31 December 2013
Prof. Dr. Luigi Terracciano
Molecular Pathology Division, Institute of Pathology, University Hospital, Schönbeinstrasse 40, CH-4003 Basel, Switzerland
Phone: +41 61 2652849
Fax: + 4161 2653194
Interests: molecular pathology; translational research; cancer stem cells; hepatic carcinogenesis; drug-induced liver diseases
In the last two decades the progress in the knowledge of molecular genetics and the availability of high-throughput technologies has offered the opportunity to identify new diagnostic and prognostic markers and new therapeutic targets in human cancer. Among the several different high-throughput technologies made available, tissue microarray (TMA) technology has significantly accelerated in situ studies of tissue specimens, to explore associations between molecular changes and clinico pathological information and to ensure preservation of unique and precious research materials. TMAs have been used for various molecular analyses that can also be performed on regular tissue sections, including immunohistochemistry, fluorescence in situ hybridization (FISH) and mRNA in situ hybridization. Virtually all kinds of tissues or cells have been converted to a microarray format. Therefore, TMA applications cover all fields of microscopic analyses of tissues and cells. In the case of cancer research, TMA has significantly facilitated the ability of basic scientists to extend in vitro studies of genes, proteins and signalling pathways to the in vivo situation radically changing the landscape of tissue-based translational research.
In this issue we are inviting material about new developments and applications of tissue microarray based technology, mainly in field of translational cancer research including screening for diagnostic, prognostic as well as predictive biomarkers, discovery of molecular alterations in different stages of tumor progression, assessment of new drug targets and quality controls.
Prof. Dr. Luigi Terracciano
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microarrays is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- tissue microarray
- high throughput
- prognostic biomarkers
- predictive biomarkers
- fluorescence in situ hybridization
- drug discovery
- quality control
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Article
Title: Clinical Grade TMA Technology for the Definition of Cancer Stem Cells and Tumor Heterogeneity
Author: Giorgio Cattoretti 1, Ida Biunno 2,3,*, Pasquale DeBlasio 4 and Aldo Scarpa 5
1 Università degli Studi Milano-Bicocca and Azienda Ospedaliera San Gerardo, Monza-Italy
2 IRGB-CNR Milano-Italy
4 Integrated System Engineering, Milano-Italy
5 University of Verona, Verona-Italy; E-Mail: email@example.com
Abstract: There is virtually an unlimited number of possible Tissue Microarray (TMA) applications in basic and clinical research and ultimately in diagnostics. The TMA asset varies according to the research goal. Highly informative arrays can be constructed from an assortment of normal and neoplastic tissues obtained as leftover materials from surgical specimens. These arrays are ideal for working up new antibodies or new probes for in situ hybridization, and quickly establish if the new marker is of interest. Tumor arrays are also being used for clinical applications in some tumor type with interesting cost-effective results. The true power of this type of approach is to correlate staining results with clinical outcome.Here we describe the use of the TMA technology in the two different settings: research and diagnostics exemplified in stem cell research and in the assessment of tumor heterogeneity.
Last update: 9 September 2013